. Author manuscript; available in PMC: 2009 Jun 10.

Published in final edited form as: Gynecol Oncol. 2007 Jul 5;106(3):469–475. doi: 10.1016/j.ygyno.2007.05.008

Table 2.

Cycles therapy administered, response and response duration

Primary Therapy	No. Patients (%)
3 - 5 cycles	5 (14%)
6 cycles	23 (66%)
> 6 cycles	7 (20%)

Second-line therapy
3-5 cycles	3 (9%)
6 cycles	31 (89%)
> 6 cycles	1 (3%)

Median CA-125 end primary therapy (range)	12 (4-31)

Median CA-125 end second-line therapy (range)	19 (3-34)

Median duration PFS1	17.8 mos, 95% CI (13.2 – 24.5 mos)

Median duration PFS2	10.8 mos, 95% CI (9.6 – 12.2 mos)

PFS1, the interval from the start of primary therapy to date of first relapse; PFS2, the interval from the start of secondary therapy to the date of the second relapse.